The desirable effects of GLP-1 on glycaemic control led to the development of a series of GLP-1 mimetics with a longer half-life than natural GLP-1 that bind and activate GLP-1R for use in the treatment of diabetes. The gene discussed is GCG; the disease is diabetes mellitus.